Mark Oertel, MD
Endocrinology, Diabetes & Metabolism · Lawrence, KSNPI 1861703860
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,460 of the $3,211 with a category attached, or 76.6%. 33 manufacturers reported payments, led by Medtronic at 34.5% of the total. Reporting peaked in 2019 at $1,284 and has fallen 59.5% since, to $521 in 2025.
Across 131 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Insulet Corporation$409
- Novo Nordisk$233
- Dexcom, Inc.$139
- Mannkind Corporation$110
- Boehringer Ingelheim$106
- plus $1K from 27 others
What the payments were for
- Travel & lodging$72723%
- Food & beverage$2,46077%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 21 | $1,107 |
| Insulet Corporation | 18 | $409 |
| Novo Nordisk | 13 | $233 |
| Dexcom, Inc. | 7 | $139 |
| Mannkind Corporation | 6 | $110 |
| Boehringer Ingelheim | 7 | $106 |
| Sanofi-aventis U.S. LLC | 4 | $94 |
| Lilly USA, LLC | 5 | $88 |
| Amgen | 5 | $77 |
| Radius Health, Inc. | 4 | $75 |
| Tandem Diabetes Care, Inc. | 4 | $75 |
| Antares Pharma, Inc. | 4 | $69 |
| AbbVie | 4 | $68 |
| Cequr Corporation | 3 | $61 |
| AstraZeneca(2 entities) | 4 | $60 |
| Ascensia Diabetes Care US Inc. | 1 | $40 |
| Alvogen Inc | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| IBSA Pharma Inc. | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Bayer | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$656
- Omnipod$148
- Minimed 530G$102
How this compares
$3,211 in reported general payments places this provider in the 60th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 314 | $381,845 |
| MounjaroTirzepatide | 179 | $199,043 |
| JardianceEmpagliflozin | 137 | $119,790 |
| Tresiba Flextouch U-100Insulin Degludec | 143 | $85,091 |
| Tresiba Flextouch U-200Insulin Degludec | 69 | $73,500 |
| FarxigaDapagliflozin Propanediol | 57 | $47,558 |
| TrulicityDulaglutide | 35 | $41,916 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 38 | $33,672 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $29,249 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 42 | $28,411 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 20 | $25,547 |
| RybelsusSemaglutide | 26 | $21,417 |
| Novolog FlexpenInsulin Aspart | 88 | $18,061 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $17,734 |
| JanuviaSitagliptin Phosphate | 24 | $15,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $233 | $434,519375 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $88 | $247,128230 claims |
| Boehringer IngelheimJardiance, Synjardy | $106 | $133,603149 claims |
| AstraZenecaFarxiga | $60 | $47,55857 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $94 | $33,67238 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $26 | $4,715442 claims |
| AbbVieSynthroid | $68 | $4,03682 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Lawrence
- Dany ZayourWichita$744K
- Andrew GreenShawnee Mission$322K
- Michael SokolOverland Park$227K
- Rami MortadaWichita$105K
- Sajeev MenonOverland Park$25K
- Georges ElhomsyWichita$14K
- Richard GomendozaSalina$13K
- John MilesKansas City$13K
- Nichole SmithMerriam$9K
- Susan BrianTopeka$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.